# The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients

Study · id `cardio:ct-nct02646267` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02646267](<https://clinicaltrials.gov/study/NCT02646267>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02646267

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

## Technical summary

Registry record NCT02646267. Randomized; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2018-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT02646267, source copy `cardio:ctgov-nct02646267-2016-01-05`, retrieved 2026-10-26)
- Start date: 2016-03 (registry gives no type) (ClinicalTrials.gov record NCT02646267, source copy `cardio:ctgov-nct02646267-2016-01-05`, retrieved 2026-10-26)
- Primary completion: 2018-01 (anticipated) (ClinicalTrials.gov record NCT02646267, source copy `cardio:ctgov-nct02646267-2016-01-05`, retrieved 2026-10-26)
- Completion: 2018-08 (anticipated) (ClinicalTrials.gov record NCT02646267, source copy `cardio:ctgov-nct02646267-2016-01-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02646267, source copy `cardio:ctgov-nct02646267-2016-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02646267-2016-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients
- Condition: Atrial Fibrillation
- Intervention (Drug): standard intensity warfarin
- Intervention (Drug): low intensity warfarin
- Intervention (Drug): dabigatran etexilate
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: 9bf6629512bf37a969f264d916b825cf14f5967f1ee7963c95c377372b4fd640
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
